ibandronic acid has been researched along with alendronate in 141 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (4.96) | 18.2507 |
| 2000's | 59 (41.84) | 29.6817 |
| 2010's | 54 (38.30) | 24.3611 |
| 2020's | 21 (14.89) | 2.80 |
| Authors | Studies |
|---|---|
| Cieslak, JA; Coates, RM; Fukura, S; Koohang, A; Lea, CR; Lee, HJ; Loftus, TC; Martin, MB; Matsumura, Y; Oldfield, E; Sagami, H; Sanders, JM; Sengupta, S; Szabo, CM | 1 |
| Martin, MB; Oldfield, E; Szabo, CM | 1 |
| Bachmann, R; Bisping, M; Born, AR; Cortesi, R; Glatt, M; Green, JR; Guiglia, G; Jaeggi, KA; Jeker, H; Klein, R; Müller, K; Ramseier, U; Schmid, J; Schreiber, G; Seltenmeyer, Y; Widler, L | 1 |
| Gossman, W; Oldfield, E | 1 |
| Burzynska, A; Gómez, AO; González-Pacanowska, D; Kafarski, P; Mao, J; Meints, GA; Oldfield, E; Sanders, JM; Van Brussel, EM | 1 |
| Burzynska, A; Chan, JM; Colantino, A; Ghosh, S; Kafarski, P; Meints, G; Morita, CT; Oldfield, E; Raker, AM; Sanders, JM; Song, Y; Wang, H | 1 |
| Araujo, FG; Chan, JM; Ling, Y; Moreno, SN; Odeh, S; Oldfield, E; Sahota, G | 1 |
| Barnett, BL; Dunford, JE; Ebetino, FH; Kavanagh, KL; Kwaasi, AA; Oppermann, U; Rogers, MJ; Russell, RG | 1 |
| Axelson, J; Cao, R; Chang, SC; Chang, TH; Guo, RT; Hudock, MP; K-M Chen, C; Ko, TP; Kumar, A; Liang, PH; No, JH; Oldfield, E; Song, Y; Wang, AH; Zhang, Y | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Altman, RA; Borel, T; Davis, I; de Azambuja, F; Johnson, D; Liu, A; Sorrentino, JP; Udokwu, C; Yang, Y | 1 |
| Almeida Paz, FA; Barbosa, JS; Braga, SS | 1 |
| Bauss, F; Bosies, E; Fleisch, H; Janner, M; Mühlbauer, RC; Schenk, R; Strein, K | 1 |
| Collin, P; Fleisch, H; Guenther, HL; Martin, TJ; Sahni, M | 1 |
| Fleisch, H; Guenther, HL; Vitté, C | 1 |
| Antic, VN; Fleisch, H; Mühlbauer, RC | 1 |
| Chilton, KM; Coxon, FP; Lawry, J; Rogers, MJ; Russell, RG; Smith, MO; Suri, S | 1 |
| Coxon, FP; Graham, R; Hughes, DE; Luckman, SP; Rogers, MJ; Russell, G | 1 |
| Alexandersen, P; Møllgaard, A; Ravn, P | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Bauer, E; Feurle, J; Kunzmann, V; Tony, HP; Weissinger, F; Wilhelm, M | 1 |
| Endo, Y; Iwakura, Y; Motegi, K; Yamaguchi, K | 1 |
| Fisher, JE; Reszka, AA; Rodan, GA | 1 |
| Faus, SA; Price, PA; Williamson, MK | 1 |
| Ravn, P | 1 |
| Christgau, S; Christiansen, C; Cloos, PA; Lehmann, HJ; Mouritzen, U | 1 |
| Frith, JC; Rogers, MJ | 1 |
| Boos, J; Lanvers-Kaminsky, C; Vorotnjak, M | 1 |
| Hosking, DJ; Pande, I | 1 |
| Chapurlat, RD | 1 |
| Wallace, DJ | 1 |
| McClung, M | 1 |
| Rackoff, PJ; Sebba, A | 1 |
| Chesnut, CH; Gass, ML; Hamdy, RC; Holick, MF; Leib, ES; Lewiecki, ME; Maricic, M; Watts, NB | 1 |
| Beusterien, K; Devas, V; Emkey, R; Kivitz, A; Koltun, W; Masanauskaite, D; Seidman, L | 1 |
| Delaney, MF | 1 |
| Delmas, PD; Emkey, R; Epstein, S; Hiltbrunner, V; Schimmer, RC; Wilson, KM | 1 |
| Dawson-Hughes, B; Gass, M | 1 |
| Franke, HR; Verdijk, R; Vermes, I; Wolbers, F | 1 |
| Brankin, E; Cooper, A; Drake, J | 1 |
| Chapurlat, RD; Delmas, PD | 1 |
| Langdahl, B; Mosekilde, L; Vestergaard, P | 1 |
| Cooper, A | 1 |
| Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B | 1 |
| Botsis, D; Christodoulakos, G; Lambrinoudaki, I | 1 |
| Curtis, JR; Saag, KG | 1 |
| Díaz-Curiel, M; Moro Alvarez, MJ | 1 |
| Malden, NJ; Pai, AY | 1 |
| McHorney, CA; Weiss, TW | 1 |
| Civitelli, R; Emkey, R; Strampel, W | 1 |
| Byrjalsen, I; Christiansen, C; Karsdal, MA; Leeming, DJ; Qvist, P | 1 |
| Rizzoli, R | 1 |
| Epstein, S; Miller, PD; Reginster, JY; Sedarati, F | 1 |
| Barrett-Connor, E; Bourgeois, P; Devas, V; Fardellone, P; Hadji, P; Licata, A; Masanauskaite, D; Minne, H; Pfeifer, M | 1 |
| Alva, D; Cesareo, R; Contini, S; De Rosa, B; Iozzino, M; Lauria, A; Mallardo, L; Napolitano, C; Orsini, A; Reda, G | 1 |
| Bergman, G; Gaugris, S; Jansen, JP; Sen, SS | 1 |
| Márton, I; Redl, P; Udvardy, E | 1 |
| Hochberg, MC | 1 |
| Burge, RT; Lindsay, R; Marshall, DA; Tosteson, AN | 1 |
| Okazaki, R | 1 |
| Bilezikian, JP | 1 |
| Aragon-Ching, JB; Arlen, PM; Chen, CC; Dahut, WL; Figg, WD; Guadagnini, JP; Gulley, JL; Latham, L; Ning, YM; Parnes, H; Wright, JJ | 1 |
| Blumentals, WA; Cole, RE; Harris, ST; Huang, L; Silverman, SL | 1 |
| Bachmann, GA; Binkley, N; Derman, RJ; Greenwald, M; Kohles, JD; Martens, MG; Silverman, SL | 1 |
| Bolognese, M; Borges, JL; Cosman, F; Delmas, PD; Emkey, R; Epstein, S; Neate, C; Ragi-Eis, S; Recknor, C; Sedarati, F; Zerbini, CA | 1 |
| Abelson, A; Gold, DT; Lange, JL; Ringe, JD; Thomas, T | 1 |
| Bivi, N; Bonetti, A; Clarke, I; Delneri, D; Harrison, R; Hoyle, DC; Moro, L; Ortolani, F; Quadrifoglio, F; Romanello, M; Tell, G | 1 |
| Chandra, M; Go, AS; Gordon, NP; Hui, RL; Hutchinson, M; Lathon, PV; Lo, JC; Martin, D; McCloskey, CA; O'Ryan, FS; Sanchez, G; Selby, JV; Silver, P; Staffa, JA; Willy, M; Yang, J | 1 |
| Glickman, G; He, J; Hsiao, A | 1 |
| Dobbins, EK; Duvall, CA; Gates, BJ; Sonnett, TE | 1 |
| Henry, C; Jahnke, W | 1 |
| Mattos, K; Migliorati, CA; Palazzolo, MJ | 1 |
| Glendenning, P; Inderjeeth, CA; Lee, S | 1 |
| Linhartova, K; Sterbakova, G; Vyskocil, V | 1 |
| Abrams, J; Bhargaval, A; Graff, JJ; Nahleh, Z; Nirmal, K | 1 |
| Pazianas, M | 1 |
| Bhattacharyya, I; Bowers, LM; Cohen, DM; Fitzpatrick, SG; Green, JG; Hinkson, DW; Neuman, AN; Stavropoulos, MF | 1 |
| Abarca, J; Campbell, HE; Martin, KE; White, TJ; Yu, J | 1 |
| Lee, YH; Song, GG | 1 |
| Bjelakovic, G; Giljaca, V; Gluud, C; Krstic, MN; Rudic, JS | 1 |
| Grätz, KW; Jacobsen, C; Metzler, P; Obwegeser, J; Rössle, M; Zemann, W | 1 |
| Diniz-Freitas, M; Diz-Dios, P; Fernández-Feijoo, J; Fernández-Sanromán, J; García-García, A; López-Cedrún, JL | 1 |
| Arias, M; Barros, X; Blasco, M; Campistol, JM; Cases, A; Durán, CE; Torregrosa, JV | 1 |
| Lo, JC; O'Ryan, FS | 1 |
| Bae, SJ; Kim, BJ; Kim, GS; Kim, HK; Koh, JM; Lee, SH; Lim, KH | 1 |
| Chen, M; Chen, Y; Chen, Z; Liu, Y; Zhu, Y | 1 |
| Yates, J | 1 |
| Cerdá, D; Gifre, L; Guañabens, N; Monegal, A; Muxí, Á; Parés, A; Peris, P | 1 |
| Diz, P; Feijoo, JF; García, A; Limeres, J; López-Cedrún, JL; Peñarrocha, M; Sanromán, JF | 1 |
| Capaldo, A; Di Somma, C; Gimigliano, F; Iolascon, G; Menditto, E; Orlando, V | 1 |
| Amling, M; Felsenberg, D; Hadji, P; Hofbauer, LC; Kandenwein, JA; Kurth, A | 1 |
| Gandhi, S; Modi, A; Sen, S; Siris, ES; Tang, J | 1 |
| Hviid, A; Pasternak, B; Svanström, H | 1 |
| Al-Rifaiy, MQ; Almas, K; Javed, F; Vohra, F | 1 |
| Alay, S; Güzelküçük, U; Kesikburun, S; Tan, AK; Yavuz, F | 1 |
| Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S | 1 |
| Eastell, R; McCloskey, E; Paggiosi, MA; Peel, N; Walsh, JS | 1 |
| Barrantes-González, M; Espona-Quer, M; Giménez-Arnau, AM; Salas, E | 1 |
| Reid, IR | 1 |
| De Luna-Bertos, E; García-Martínez, O; Manzano-Moreno, FJ; Ramos-Torrecillas, J; Ruiz, C | 1 |
| Modi, A; Sajjan, S; Siris, ES; Steve Fan, CP | 1 |
| Eastell, R; Gossiel, F; Jacques, RM; McCloskey, EV; Naylor, KE; Paggiosi, M; Peel, NF; Walsh, JS | 1 |
| Chen, LX; Feng, SQ; Li, YL; Ning, GZ; Zhang, D; Zhang, TS; Zhou, ZR | 1 |
| Di Bonito, M; Ferretti, V; Giampà, E; Nuvoli, G; Paoletti, F; Piazzini, M; Ranieri, M; Tuveri, MA; Vinicola, V | 1 |
| Adami, S; Gatti, D; Rossini, M; Viapiana, O | 1 |
| Ju, JH; Jung, SM; Koh, JH; Kwok, SK; Lee, J; Myong, JP; Park, SH | 1 |
| Ataoğlu, B; Berkay, AF; Eren, TK; Kaptan, AY; Yapar, AE | 1 |
| Etminan, M; Guo, M; Maberley, D; Mammo, Z; Matsubara, J | 1 |
| Mészaros, Á; Veszelyné Kotán, E | 2 |
| González, R; López-Posadas, R; Martínez-Augustin, O; Mascaraque, C; Sánchez de Medina, F; Suárez, MD; Zarzuelo, A | 1 |
| Kõks, S; Laius, O; Maasalu, K; Märtson, A | 1 |
| Campbell, F; Davis, S; Gittoes, N; Goka, E; Martyn-St James, M; Rawdin, A; Sadler, S; Sanderson, J; Selby, P; Stevens, J; Stevenson, M; Strong, M; Wong, R | 1 |
| Jiang, LA; Leder, BZ; Lee, H; Tsai, JN | 1 |
| Baek, GH; Gong, HS; Noh, JH; Roh, YH | 1 |
| Al-Nawas, B; Jung, J; Kwon, YD; Pabst, AM; Park, JS; Righesso, L; Walter, C | 1 |
| Ciornohac, JF; Mathonet, PY; Willems, S | 1 |
| Bradburn, M; Eastell, R; Gossiel, F; McCloskey, EV; Naylor, KE; Paggiosi, MA; Peel, NFA; Walsh, JS | 1 |
| Hongo, M; Horikawa, A; Kasukawa, Y; Kodama, H; Miyakoshi, N; Shimada, Y | 1 |
| Costela-Ruiz, VJ; García-Martínez, O; Illescas-Montes, R; Manzano-Moreno, FJ; Melguizo-Rodriguez, L; Ramos-Torrecillas, J; Ruiz, C | 1 |
| Eastell, R; Fontalis, A | 1 |
| Ballal, P; Duryea, J; Lu, N; Neogi, T; Ratzlaff, C; Sury, M; Zhang, Y | 1 |
| Cunningham, J; Hildebrand, S | 1 |
| Betsch, M; Colarossi, G; Eschweiler, J; Maffulli, N; Migliorini, F; Tingart, M | 1 |
| Kaseda, R; Mitsuboshi, S; Narita, I | 1 |
| Atar, S; Demirhan, E; Er, G; Kuru, Ö; Yurttaser, SO | 1 |
| Baim, S; Bedrose, S; Casagrande, A; Go, MT; Goel, M; Hanna, M; Husni, H; Li, D; Mahrous, P; Morkos, M | 1 |
| Chen, CH; Chen, WJ; Chen, YM; Chien, LN; Ku, CK; Li, CY; Lin, SY | 1 |
| Hadjiargyrou, M | 1 |
| Huang, J; Li, P; Li, Y; Wu, X | 1 |
| McConnell, M; Shieh, A | 1 |
| Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T | 2 |
| Ehrenstein, V; Kafatos, G; Neasham, D; O'Kelly, J; Pedersen, AB; Risbo, N | 1 |
| Alves, C; Batel-Marques, F; Donato, A; Mendes, D; Oliveira, T; Penedones, A | 1 |
| Chan, DC; Chang, YF; Chen, HM; Fu, SH; Hsu, CC; Hwang, JS; Lin, JW; Wang, CY; Wu, CH; Yang, RS; Yang, TH | 1 |
| Chen, Y; Huang, Y; Xiao, Y | 1 |
| Bonel, H; Everts-Graber, J; Gahl, B; Häuselmann, H; Lehmann, D; Lehmann, T; Reichenbach, S; Studer, U; Ziswiler, HR | 1 |
| Bastounis, A; Bishop, S; Corp, N; Gittoes, N; Griffin, J; Langley, T; Leonardi-Bee, J; Narayanasamy, MJ; Paskins, Z; Sahota, O | 1 |
43 review(s) available for ibandronic acid and alendronate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug Compounding; Drug Delivery Systems; Humans | 2021 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
Bisphosphonates for prevention of postmenopausal osteoporosis.
Topics: Alendronate; Biomarkers; Bone Density; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic | 2002 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Fractures, Bone; Glucocorticoids; Humans; Ibandronic Acid; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide | 2005 |
Rapid prevention of vertebral fractures associated with osteoporosis.
Topics: Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; Estrogens; Female; Glucocorticoids; Humans; Ibandronic Acid; Imidazoles; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risk Factors; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2005 |
Use of highly potent bisphosphonates in the treatment of osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Remodeling; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Prognosis; Randomized Controlled Trials as Topic; Risedronic Acid; Severity of Illness Index; Treatment Outcome | 2003 |
Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2005 |
Review of treatment modalities for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Diet; Dietary Supplements; Diphosphonates; Etidronic Acid; Exercise; Female; Fish Oils; Hip Fractures; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Teriparatide; Vitamin D; Vitamin D Deficiency | 2005 |
Strategies for the prevention and treatment of osteoporosis during early postmenopause.
Topics: Accidental Falls; Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Exercise; Female; Humans; Ibandronic Acid; Life Style; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Perimenopause; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Vitamin D | 2006 |
Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Fractures, Bone; Gastrointestinal Diseases; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2006 |
Preventing osteoporosis-related fractures: an overview.
Topics: Absorptiometry, Photon; Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Dietary Supplements; Diphosphonates; Etidronic Acid; Exercise; Female; Fractures, Bone; Humans; Ibandronic Acid; Motor Activity; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Risedronic Acid; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Teriparatide; United States; Vitamin D | 2006 |
Drug insight: Bisphosphonates for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2006 |
Fracture prevention in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Hormone Replacement Therapy; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Pamidronate; Parathyroid Hormone; Risedronic Acid; Selective Estrogen Receptor Modulators; Vitamin D | 2006 |
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Osteonecrosis; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2006 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2006 |
Pharmacological treatment of osteoporosis for people over 70.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risedronic Acid; Thiophenes; Vitamin D | 2007 |
Safety considerations with bisphosphonates for the treatment of osteoporosis.
Topics: Acute-Phase Reaction; Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Injections, Intravenous; Jaw Diseases; Osteonecrosis; Osteoporosis, Postmenopausal; Renal Insufficiency; Risedronic Acid | 2007 |
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes; Vitamin D | 2007 |
[Osteonecrosis of the jaw developing during bisphosphonate treatment].
Topics: Alendronate; Anti-Infective Agents; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Mandible; Mandibular Diseases; Oral Hygiene; Oral Surgical Procedures; Osteonecrosis; Patient Care Team; Referral and Consultation; Zoledronic Acid | 2008 |
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Male; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Spinal Fractures; Zoledronic Acid | 2008 |
[New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Patient Compliance; Risedronic Acid; Zoledronic Acid | 2009 |
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2009 |
Review of osteoporosis pharmacotherapy for geriatric patients.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Economics, Pharmaceutical; Etidronic Acid; Exercise; Female; Humans; Ibandronic Acid; Life Style; Male; Osteonecrosis; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Vitamin D | 2009 |
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Patient Compliance; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Treatment Outcome | 2011 |
Osteonecrosis of the jaw and the role of macrophages.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Indoles; Jaw Diseases; Macrophages; Magnetic Resonance Imaging; Mevalonic Acid; Monocytes; Mouth Mucosa; Osteoclasts; Osteomyelitis; Osteonecrosis; Positron-Emission Tomography; Pyrroles; Radiography, Panoramic; RANK Ligand; Risedronic Acid; Risk Factors; Signal Transduction; Sunitinib; Tomography, X-Ray Computed; Vitamin D; Zoledronic Acid | 2011 |
Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials.
Topics: Administration, Oral; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Evidence-Based Medicine; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Patient Preference; Radiography; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2011 |
Bisphosphonates for osteoporosis in primary biliary cirrhosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Liver Cirrhosis, Biliary; Male; Osteoporosis; Randomized Controlled Trials as Topic | 2011 |
A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Spine | 2013 |
Efficacy of systemic bisphosphonate delivery on osseointegration of implants under osteoporotic conditions: lessons from animal studies.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Dental Implantation, Endosseous; Dental Implants; Dental Restoration Failure; Diphosphonates; Female; Ibandronic Acid; Imidazoles; Osseointegration; Osteoporosis; Ovariectomy; Surface Properties; Zoledronic Acid | 2014 |
Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Ibandronic Acid; Incidence; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Therapeutic Equivalency | 2014 |
Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Hydroxycholecalciferols; Ibandronic Acid; Imidazoles; Lumbar Vertebrae; Osteoporosis; Parathyroid Hormone; Risedronic Acid; Teriparatide; Thiophenes; Zoledronic Acid | 2015 |
The use of bisphosphonates in women: when to use and when to stop.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Factors; Time Factors; Zoledronic Acid | 2015 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid | 2016 |
A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Topics: Alendronate; Bone Density Conservation Agents; Cost of Illness; Cost-Benefit Analysis; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Models, Econometric; Osteoporotic Fractures; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Social Work; State Medicine; United Kingdom; Zoledronic Acid | 2016 |
The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal | 2020 |
Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis.
Topics: Alendronate; Bayes Theorem; Bone Density; Bone Density Conservation Agents; Denosumab; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Pharmaceutical Preparations | 2021 |
Effects of bisphosphonates on appendicular fracture repair in rodents.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Denosumab; Diphosphonates; Estrogens; Femoral Fractures; Fractures, Stress; Glucocorticoids; Ibandronic Acid; Mice; Rats; Rodentia | 2022 |
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Male; Network Meta-Analysis; Osteoporosis; Risedronic Acid; Spinal Fractures; Zoledronic Acid | 2022 |
Polypharmacy in Osteoporosis Treatment.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Polypharmacy; Risedronic Acid; Teriparatide; Zoledronic Acid | 2022 |
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Male; Neoplasms; Network Meta-Analysis; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2023 |
Ibandronate in the Prevention of Vertebral and Nonvertebral Osteoporotic Fractures: A Systematic Review of Experimental and Observational Studies.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Observational Studies as Topic; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid | 2023 |
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome | 2023 |
19 trial(s) available for ibandronic acid and alendronate
| Article | Year |
|---|---|
Bone densitometry: a new, highly responsive region of interest in the distal forearm to monitor the effect of osteoporosis treatment.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Analysis of Variance; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Estrogen Replacement Therapy; Female; Humans; Ibandronic Acid; Image Processing, Computer-Assisted; Linear Models; Male; Middle Aged; Osteoporosis, Postmenopausal; Radius; Sensitivity and Specificity; Ulna | 1999 |
Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products.
Topics: Alendronate; Analysis of Variance; Bone Resorption; Cartilage; Collagen Type I; Collagen Type II; Diphosphonates; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis | 2002 |
Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Cross-Over Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Prospective Studies | 2005 |
Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Social Support; Treatment Outcome | 2006 |
Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Collagen; Collagen Type I; Diphosphonates; Double-Blind Method; Estrogen Replacement Therapy; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride | 2008 |
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome | 2008 |
Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cross-Over Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Prospective Studies; Treatment Outcome | 2008 |
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
Topics: Adult; Aged; Alendronate; Angiogenesis Inhibitors; Diphosphonates; Humans; Ibandronic Acid; Incidence; Jaw Diseases; Male; Middle Aged; Neoplasm Metastasis; Osteonecrosis; Prostatic Neoplasms | 2009 |
Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Gastroesophageal Reflux; Heartburn; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Risedronic Acid | 2009 |
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Treatment Outcome | 2009 |
Successful treatment of calcific uraemic arteriolopathy with bisphosphonates.
Topics: Aged; Alendronate; Alkaline Phosphatase; Arterioles; Calciphylaxis; Calcium; Comorbidity; Diphosphonates; Disease Progression; Etidronic Acid; Female; Humans; Hyperparathyroidism, Secondary; Ibandronic Acid; Kidney Transplantation; Male; Middle Aged; Parathyroid Hormone; Parathyroidectomy; Phosphates; Prospective Studies; Renal Dialysis; Risedronic Acid; Skin; Uremia | 2012 |
Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Ibandronic Acid; Liver Cirrhosis, Biliary; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Treatment Outcome | 2013 |
The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Analgesics; Bone Density Conservation Agents; Diphosphonates; Drug Utilization; Female; Humans; Ibandronic Acid; Injections, Intravenous; Kaplan-Meier Estimate; Medication Adherence; Middle Aged; Motor Activity; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Treatment Outcome | 2014 |
Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Hip Joint; Humans; Ibandronic Acid; Lower Extremity; Lumbar Vertebrae; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Upper Extremity | 2014 |
Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Premenopause; Reference Values; Risedronic Acid; Treatment Outcome | 2016 |
Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Teriparatide; Zoledronic Acid | 2017 |
Comparative adherence to weekly oral and quarterly intravenous bisphosphonates among patients with limited heath literacy who sustained distal radius fractures.
Topics: Administration, Intravenous; Administration, Oral; Alendronate; Bone Density Conservation Agents; Demography; Diphosphonates; Drug Administration Schedule; Female; Health Education; Humans; Ibandronic Acid; Injections, Intravenous; Medication Adherence; Middle Aged; Multivariate Analysis; Osteoporosis, Postmenopausal; Radius Fractures | 2018 |
Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Female; Hip Joint; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Withholding Treatment | 2018 |
A prospective comparative study of intravenous alendronate and ibandronate for the treatment of osteoporosis.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Prospective Studies; Treatment Outcome | 2019 |
79 other study(ies) available for ibandronic acid and alendronate
| Article | Year |
|---|---|
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents.
Topics: Alkyl and Aryl Transferases; Antiparasitic Agents; Bone Resorption; Diphosphonates; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Models, Molecular; Organophosphates; Quantitative Structure-Activity Relationship; Recombinant Proteins | 2002 |
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Quantitative Structure-Activity Relationship; Rats | 2002 |
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
Topics: Animals; Bone Resorption; Calcitriol; Diphosphonates; Hypercalcemia; Imidazoles; In Vitro Techniques; Kidney; Mice; Pamidronate; Parathyroidectomy; Rats; Skull; Structure-Activity Relationship; Thyroidectomy; Zoledronic Acid | 2002 |
Quantitative structure--activity relations for gammadelta T cell activation by phosphoantigens.
Topics: Antigens, Bacterial; Lymphocyte Activation; Models, Molecular; Phosphoproteins; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes | 2002 |
3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.
Topics: Animals; Crystallography, X-Ray; Dimethylallyltranstransferase; Diphosphonates; Imidazoles; Leishmania major; Models, Molecular; Picolinic Acids; Pyridines; Quantitative Structure-Activity Relationship; Zoledronic Acid | 2003 |
Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
Topics: Alkyl and Aryl Transferases; Animals; Cell Division; Cell Line; Diphosphonates; Geranyltranstransferase; Humans; Leishmania major; Lymphocyte Activation; Models, Molecular; Quantitative Structure-Activity Relationship; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2004 |
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
Topics: Aldose-Ketose Isomerases; Alkyl and Aryl Transferases; Animals; Antiprotozoal Agents; Cell Line; Diphosphonates; Fosfomycin; Geranyltranstransferase; Humans; Mice; Models, Molecular; Multienzyme Complexes; Oxidoreductases; Quantitative Structure-Activity Relationship; Toxoplasma; Toxoplasmosis | 2005 |
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
Topics: Binding Sites; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Models, Molecular; Molecular Structure; Nitrogen; Stereoisomerism; Structure-Activity Relationship; Time Factors | 2008 |
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.
Topics: Antineoplastic Agents; Crystallography, X-Ray; Diphosphonates; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Farnesyltranstransferase; Humans; K562 Cells; Magnetic Resonance Spectroscopy; Models, Molecular; Quantitative Structure-Activity Relationship | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
Topics: Bacterial Proteins; Binding Sites; Biosynthetic Pathways; Carboxy-Lyases; Catalytic Domain; Crystallography, X-Ray; Diflunisal; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kynurenine; Molecular Docking Simulation; NAD; Pseudomonas fluorescens; Structure-Activity Relationship; Tryptophan | 2021 |
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Topics: Alendronate; Animals; Benzoates; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Ibandronic Acid; Injections, Intravenous; Osteoclasts; Pamidronate; Rats; Retinoids; Risedronic Acid; Spectrophotometry, Atomic; Tetracycline; Thyroxine | 1991 |
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.
Topics: Alendronate; Animals; Animals, Newborn; Bone Resorption; Cell Line; Cells, Cultured; Clodronic Acid; Culture Media, Conditioned; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Ibandronic Acid; Kinetics; Osteoblasts; Pamidronate; Parathyroid Hormone; Rats; Rats, Wistar; Time Factors | 1993 |
Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption.
Topics: Acid Phosphatase; Alendronate; Animals; Bone Resorption; Cell Line; Culture Media, Conditioned; Diphosphonates; Endopeptidases; Hot Temperature; Ibandronic Acid; Isoenzymes; Kinetics; Molecular Weight; Osteoblasts; Osteoclasts; Rats; Rats, Wistar; Tartrate-Resistant Acid Phosphatase | 1996 |
Effect of bisphosphonates on the increase in bone resorption induced by a low calcium diet.
Topics: Alendronate; Animals; Bone Resorption; Calcium; Calcium, Dietary; Clodronic Acid; Diphosphonates; Disease Models, Animal; Homeostasis; Ibandronic Acid; Male; Rats; Rats, Wistar; Tetracycline | 1996 |
Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism.
Topics: Alendronate; Animals; Apoptosis; Bone Marrow; Bone Marrow Cells; Bone Resorption; Cell Division; Cell Nucleus; Cells, Cultured; Diphosphonates; DNA; DNA Fragmentation; Electrophoresis, Polyacrylamide Gel; Ibandronic Acid; Macrophages; Mice; Necrosis; Nitric Oxide; Pamidronate; Protein Biosynthesis | 1996 |
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Topics: Alendronate; Animals; Apoptosis; Bone Resorption; Cells, Cultured; Clodronic Acid; Diphosphonates; Enzyme Inhibitors; Etidronic Acid; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Ibandronic Acid; Lovastatin; Macrophages; Mevalonic Acid; Mice; Osteoclasts; Protein Prenylation; Protein Processing, Post-Translational; ras Proteins; Risedronic Acid; Structure-Activity Relationship | 1998 |
Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.
Topics: Alendronate; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Bone Marrow Cells; Cell Division; Cell Survival; Cytotoxicity, Immunologic; Diphosphonates; Humans; Ibandronic Acid; Interferon-gamma; Interleukin-2; Kinetics; Lectins, C-Type; Lymphocyte Activation; Multiple Myeloma; Pamidronate; Plasma Cells; Receptors, Interleukin-2; T-Lymphocytes; Tumor Cells, Cultured | 2000 |
Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice.
Topics: Alendronate; Animals; Diphosphonates; Drug Interactions; Escherichia coli; Histidine Decarboxylase; Ibandronic Acid; Inflammation; Interleukin-1; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Mice, Knockout; Prevotella intermedia | 2000 |
In vivo effects of bisphosphonates on the osteoclast mevalonate pathway.
Topics: Alendronate; Alkyl and Aryl Transferases; Animals; Bone Resorption; Diphosphonates; Enzyme Inhibitors; Etidronic Acid; Geranyltranstransferase; Hydroxymethylglutaryl CoA Reductases; Ibandronic Acid; Male; Mevalonic Acid; Osteoclasts; Rats; Rats, Sprague-Dawley; Risedronic Acid | 2000 |
Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption.
Topics: Alendronate; Animals; Aortic Diseases; Bone Resorption; Calcification, Physiologic; Calcinosis; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Male; Muscle, Smooth, Vascular; Osteoporosis; Rats; Rats, Sprague-Dawley; Vitamin D; Warfarin | 2001 |
Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.
Topics: Adenosine Triphosphate; Alendronate; Animals; Apoptosis; Blotting, Western; Bone Resorption; Cell Line; Cell Membrane; Cell Nucleus; Cells, Cultured; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Ibandronic Acid; Macrophages; Mice; Microscopy, Fluorescence; Osteoclasts; Pinocytosis; Rabbits; Time Factors | 2003 |
In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
Topics: Alendronate; Apoptosis; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Diphosphonates; Drug Screening Assays, Antitumor; Germany; Humans; Ibandronic Acid; Imidazoles; Neuroblastoma; Pamidronate; Time Factors; Zoledronic Acid | 2004 |
Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2005 |
Differential effects of bisphosphonates on breast cancer cell lines.
Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Cyclin D1; Diphosphonates; DNA Fragmentation; Etidronic Acid; Female; Flow Cytometry; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Risedronic Acid; RNA, Messenger; Zoledronic Acid | 2007 |
Compliance with treatment for osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Patient Compliance | 2006 |
Prevention and treatment of glucocorticoid-induced osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Calcium; Cost-Benefit Analysis; Diphosphonates; Etidronic Acid; Female; Glucocorticoids; Humans; Ibandronic Acid; Male; Osteoporosis; Parathyroid Hormone; Patient Compliance; Practice Guidelines as Topic; Quality of Health Care; Rheumatic Diseases; Time Factors; Vitamin D; Vitamin K | 2007 |
Bisphosphonates. A cornerstone of osteoporosis treatment.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Ibandronic Acid; Mandibular Diseases; Osteonecrosis; Osteoporosis; Risedronic Acid | 2007 |
Oral bisphosphonate associated osteonecrosis of the jaws: three case reports.
Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chlorhexidine; Clindamycin; Diphosphonates; Etidronic Acid; Facial Pain; Female; Humans; Ibandronic Acid; Jaw Diseases; Middle Aged; Oral Fistula; Osteonecrosis; Penicillin V; Risedronic Acid; Tooth Extraction | 2007 |
Osteoporosis medication profile preference: results from the PREFER-US study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Internet; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Socioeconomic Factors; Time Factors | 2007 |
Osteoporosis: non-hormonal treatment.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Denosumab; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Thiophenes; Vitamin D; Women's Health | 2007 |
Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cholecalciferol; Cost-Benefit Analysis; Diphosphonates; Drug Combinations; Drug Costs; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Models, Economic; Netherlands; Osteoporosis; Patient Compliance; Patient Simulation; Quality-Adjusted Life Years; United Kingdom | 2008 |
Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Budgets; Cost-Benefit Analysis; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Health Care Costs; Humans; Ibandronic Acid; Markov Chains; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Risedronic Acid; Risk Assessment; Risk Factors; United States | 2008 |
Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
Topics: Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Retrospective Studies; Risedronic Acid; Risk Factors | 2009 |
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Epidemiologic Methods; Etidronic Acid; Female; Hip Fractures; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid; United States | 2010 |
Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection.
Topics: Alendronate; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Movement; Diphosphonates; DNA Breaks, Double-Stranded; DNA Damage; Etidronic Acid; Gene Deletion; Humans; Ibandronic Acid; Microscopy, Confocal; Microscopy, Electron; Microtubules; Mutation; Polyisoprenyl Phosphates; Risedronic Acid; RNA Interference; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins | 2009 |
Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; California; Cross-Sectional Studies; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Jaw Diseases; Male; Osteonecrosis; Prevalence; Risedronic Acid; Surveys and Questionnaires; Tooth Extraction | 2010 |
A retrospective clinical and radiographic study on healing of periradicular lesions in patients taking oral bisphosphonates.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Composite Resins; Diphosphonates; Etidronic Acid; Follow-Up Studies; Gutta-Percha; Humans; Ibandronic Acid; Middle Aged; Periapical Diseases; Radiography; Retrospective Studies; Risedronic Acid; Root Canal Filling Materials; Root Canal Preparation; Single-Blind Method; Treatment Outcome; Wound Healing | 2009 |
An in vitro assay to measure targeted drug delivery to bone mineral.
Topics: Alendronate; Anabolic Agents; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Drug Delivery Systems; Durapatite; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Nuclear Magnetic Resonance, Biomolecular; Pamidronate; Risedronic Acid; Zoledronic Acid | 2010 |
How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Dental Care; Diphosphonates; Etidronic Acid; Female; Health Knowledge, Attitudes, Practice; Humans; Ibandronic Acid; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Osteoporosis; Patient Education as Topic; Risedronic Acid; Risk Factors; Time Factors | 2010 |
Bisphosphonates in calcific aortic stenosis: association with slower progression in mild disease--a pilot retrospective study.
Topics: Aged; Alendronate; Aortic Valve Stenosis; Bone Density Conservation Agents; Calcinosis; Comorbidity; Diphosphonates; Disease Progression; Female; Hemodynamics; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Pilot Projects; Retrospective Studies | 2010 |
Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Michigan; Middle Aged; Neoplasm Staging; Population Surveillance; Registries; Retrospective Studies; Risedronic Acid; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2010 |
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Mandibular Diseases; Maxillary Diseases; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Tooth Extraction; Tooth Socket; Zoledronic Acid | 2012 |
Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Comparative Effectiveness Research; Diphosphonates; Drug Costs; Etidronic Acid; Female; Follow-Up Studies; Fractures, Bone; Humans; Ibandronic Acid; Insurance Claim Review; Longitudinal Studies; Male; Managed Care Programs; Medication Adherence; Middle Aged; Osteoporosis; Regression Analysis; Retrospective Studies; Risedronic Acid; United States | 2011 |
Osteopathology induced by bisphosphonates and dental implants: clinical observations.
Topics: Actinomycosis; Administration, Intravenous; Administration, Oral; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Debridement; Dental Implants; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Male; Mandible; Mandibular Neoplasms; Maxilla; Neoplasms; Osteomyelitis; Osteoporosis; Pamidronate; Risk Factors; Time Factors; Zoledronic Acid | 2013 |
Oral bisphosphonate-related osteonecrosis of the jaws: Clinical characteristics of a series of 20 cases in Spain.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Male; Middle Aged; Retrospective Studies; Spain | 2012 |
Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antirheumatic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Chronic Disease; Cohort Studies; Debridement; Diphosphonates; Female; Follow-Up Studies; Glucocorticoids; Humans; Ibandronic Acid; Male; Middle Aged; Osteolysis; Osteoporosis; Osteosclerosis; Retrospective Studies; Tooth Extraction; Treatment Outcome; Wound Healing | 2012 |
Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Injections, Intravenous; Longitudinal Studies; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Postmenopause; Retrospective Studies; Risedronic Acid | 2012 |
[Simultaneous determination of alendronate, pamidronate, ibandronate and risedronate using ion chromatography with integrated pulsed amperometric detection].
Topics: Alendronate; Chromatography, Ion Exchange; Diphosphonates; Electrochemical Techniques; Etidronic Acid; Humans; Ibandronic Acid; Pamidronate; Risedronic Acid | 2012 |
Oral bisphosphonate-related osteonecrosis of the jaws in dental implant patients: a case series.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Dental Implants; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Hypertension; Ibandronic Acid; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Retrospective Studies; Risedronic Acid; Risk Factors; Time Factors | 2013 |
Osteoporosis drugs in real-world clinical practice: an analysis of persistence.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Etidronic Acid; Female; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Retrospective Studies; Risedronic Acid; Thiophenes | 2013 |
Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Managed Care Programs; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Teriparatide; United States; Zoledronic Acid | 2014 |
Use of strontium ranelate and risk of acute coronary syndrome: cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denmark; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Risedronic Acid; Thiophenes | 2014 |
Exacerbation of myasthenia gravis by alendronate.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Glucocorticoids; Humans; Ibandronic Acid; Male; Myasthenia Gravis; Osteoporosis; Young Adult | 2014 |
Bisphosphonate-induced cutaneous adverse events: the difficulty of assessing imputability through patch testing.
Topics: Aged; Alendronate; Case-Control Studies; Diphosphonates; Drug Eruptions; Female; Humans; Ibandronic Acid; Male; Patch Tests; Reference Values; Retrospective Studies; Sampling Studies; Sensitivity and Specificity; Severity of Illness Index | 2014 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid | 2015 |
High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis.
Topics: Alendronate; Apoptosis; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Coloring Agents; Diphosphonates; Dose-Response Relationship, Drug; Flow Cytometry; G1 Phase; Humans; Ibandronic Acid; Necrosis; Osteoblasts; Pamidronate; Resting Phase, Cell Cycle; Spectrophotometry; Tetrazolium Salts; Thiazoles; Time Factors | 2015 |
Gastrointestinal Events Among Patients Initiating Osteoporosis Therapy: A Retrospective Administrative Claims Database Analysis.
Topics: Administrative Claims, Healthcare; Aged; Alendronate; Databases, Factual; Diphosphonates; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Retrospective Studies; Risedronic Acid; United States | 2015 |
Results of a national multicentric study on compliance to treatment with various disphosphonate formulations in patients with postmenopausal osteoporosis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid | 2015 |
Atypical Femoral Fracture in Rheumatoid Arthritis Patients Treated With Bisphosphonates: A Nested Case-Control Study.
Topics: Absorptiometry, Photon; Aged; Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Female; Femoral Fractures; Femur; Genu Valgum; Humans; Ibandronic Acid; Logistic Models; Lumbar Vertebrae; Middle Aged; Multivariate Analysis; Osteoporotic Fractures; Retrospective Studies; Risedronic Acid; Risk Factors; Time Factors | 2016 |
Atypical femoral fracture following zoledronic acid treatment.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Female; Femoral Fractures; Fracture Fixation; Humans; Ibandronic Acid; Imidazoles; Magnetic Resonance Imaging; Osteoporosis; Treatment Outcome; Withholding Treatment; Zoledronic Acid | 2016 |
Oral Bisphosphonates and Risk of Wet Age-Related Macular Degeneration.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Case-Control Studies; Diphosphonates; Female; Humans; Ibandronic Acid; Male; Odds Ratio; Risedronic Acid; Risk Factors; Wet Macular Degeneration | 2016 |
[Bisphosphonate use and related pharmaceutical issues II].
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Confounding Factors, Epidemiologic; Diphosphonates; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Hungary; Ibandronic Acid; Imidazoles; National Health Programs; Osteoporosis; Pamidronate; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2016 |
The Bisphosphonate Pamidronate is an Intestinal Antiinflammatory Agent in Rat and Mouse Experimental Colitis.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Colitis; Dextran Sulfate; Diphosphonates; Ibandronic Acid; Immunologic Factors; Intestinal Mucosa; Mice; Pamidronate; Rats; T-Lymphocytes; Trinitrobenzenesulfonic Acid | 2016 |
Use of drugs against osteoporosis in the Baltic countries during 2010-2014.
Topics: Alendronate; Baltic States; Bone Density Conservation Agents; Calcium Channel Blockers; Denosumab; Diphosphonates; Drug Utilization; Ergocalciferols; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Risedronic Acid | 2016 |
Effects of an oral bisphosphonate and three intravenous bisphosphonates on several cell types in vitro.
Topics: Administration, Oral; Alendronate; Apoptosis; Cell Movement; Cell Survival; Cells, Cultured; Clodronic Acid; Diphosphonates; Endothelial Cells; Fibroblasts; Humans; Ibandronic Acid; In Vitro Techniques; Infusions, Intravenous; Osteoblasts; Zoledronic Acid | 2018 |
[Subtrochanteric pathological fracture on bisphosphonates].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Spontaneous; Hip Fractures; Humans; Ibandronic Acid | 2018 |
Impact of bisphosphonates on the proliferation and gene expression of human fibroblasts.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Cell Differentiation; Cell Proliferation; Diphosphonates; Fibroblasts; Gene Expression Regulation; Humans; Ibandronic Acid; Jaw; Osteoblasts; Real-Time Polymerase Chain Reaction; Zoledronic Acid | 2019 |
The relation of oral bisphosphonates to bone marrow lesion volume among women with osteoarthritis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Marrow; Diphosphonates; Female; Humans; Ibandronic Acid; Longitudinal Studies; Magnetic Resonance Imaging; Middle Aged; Osteoarthritis, Knee; Propensity Score; Risedronic Acid | 2020 |
Is there a role for bisphosphonates in vascular calcification in chronic kidney disease?
Topics: Alendronate; Diphosphonates; Female; Humans; Ibandronic Acid; Renal Insufficiency, Chronic; Vascular Calcification | 2021 |
Association Between Antiosteoporotic Drugs and Risk of Acute Kidney Injury: A Cross-Sectional Study Using Disproportional Analysis and a Pharmacovigilance Database.
Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Alendronate; Cross-Sectional Studies; Databases, Factual; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Osteoporosis; Pharmaceutical Preparations; Pharmacovigilance; Selective Estrogen Receptor Modulators; Teriparatide | 2022 |
The ocular findings related to oral bisphosphonate use.
Topics: Administration, Oral; Alendronate; Diphosphonates; Female; Humans; Ibandronic Acid | 2022 |
Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies; Teriparatide; United States; Zoledronic Acid | 2022 |
Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Female; Humans; Ibandronic Acid; Male; Medication Adherence; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Taiwan; Teriparatide; Zoledronic Acid | 2022 |
Utilization patterns and factors associated with persistence of new users of anti-osteoporosis treatment in Denmark: a population-based cohort study.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Denmark; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2023 |
Constraining in reimbursement criteria and the adherence to anti-osteoporosis medications (AOMs) in Taiwan: Urbanization makes the difference.
Topics: Alendronate; Bone Density Conservation Agents; Humans; Ibandronic Acid; Osteoporosis; Taiwan; Urbanization | 2023 |
Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Femur; Humans; Ibandronic Acid; Osteoporosis; Pamidronate; Pharmaceutical Preparations; Risedronic Acid | 2023 |
Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Hip Fractures; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Registries; Spinal Fractures; Zoledronic Acid | 2023 |
Clinicians' views of prescribing oral and intravenous bisphosphonates for osteoporosis: a qualitative study.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal; Zoledronic Acid | 2023 |